Xarelto® Lawsuit Update: Roger C. Denton of Schlichter, Bogard & Denton, LLP Appointed to Plaintiffs’ Steering Committee
On February 9, 2015 the Honorable Eldon Fallon, sitting in the U.S. District Court for the Eastern District of Louisiana, appointed Roger C. Denton of Schlichter, Bogard & Denton, LLP to the Plaintiffs’ Steering Committee (PSC) in the national Xarelto® Multidistrict Litigation (In Re: Xarelto (Rivaroxaban) Products Liability Litigation, Case No. 2:14-md-02592, MDL 2592, Pretrial Order #7). As a member of the PSC, Roger Denton will perform vital and exclusive functions, which include initiating and coordinating discovery, examining witnesses, managing bellwether cases, and appearing before the court on behalf of all plaintiffs who contend to have been harmed by Xarelto®.
Xarelto® (Rivaroxaban) is a blood thinning medication alleged to cause serious and uncontrolled internal bleeding, particularly gastrointestinal bleeding, that could result in severe injuries, or even death. “We will fight for the rights of individuals who allege to have experienced serious and life-threatening injuries after taking Xarelto®,” says Denton.
Roger C. Denton is a national trial attorney who has also served as Co-Lead Counsel on the Plaintiffs’ Steering Committee in the Pradaxa® Multidistrict Litigation (MDL 2385). Denton was later appointed by Chief Judge David R. Herndon to serve as a member of the Pradaxa® Claimants’ Negotiating Committee (PCNC) to negotiate a settlement on behalf of all plaintiffs claiming injury after using Pradaxa®. As Co-Lead Counsel and member of the PCNC, Denton played a critical role in bringing the Pradaxa® Litigation to resolution, resulting in a $650 million settlement for the plaintiffs.
Schlichter, Bogard & Denton, LLP is a unique law firm that has held numerous leadership positions in national litigations involving dangerous pharmaceutical medications and unsafe medical devices, including but not limited to: In re: Pradaxa® (Dabigatran Etexilate) Products Liability (MDL 2385, Case No. 12-md-2385, S.D. Ill.), In re: Yasmin® and Yaz® (Drospirenone) Marketing and Sales Practices and Products Liability Litigation (MDL 2100, Case No. 09-md-2100, S.D. Ill.), In re: NuvaRing® Products Liability Litigation (MDL 1964, Case No. 08-md-1964, E.D. Mo.), In re: Gadolinium-Based Contrast Products Liability Litigation (MDL 1909, Case No. 08-md-50000, N.D. Ohio), and In re: Ortho Evra® Products Liability Litigation (MDL 1742, Case No. 06-md-40000, N.D. Ohio).
The Pharmaceuticals and Medical Litigation Department at Schlichter, Bogard & Denton aggressively represent clients who allege to have suffered injuries as a result of dangerous pharmaceutical medications and unsafe medical devices. The attorneys at Schlichter, Bogard & Denton, LLP who represent such victims include Roger Denton, Kristine Kraft, Beth Wilkins Flieger, Ashley Brittain Landers, Tara Rocque, and Rachel Harris. With hard work, creative thinking, and strong trial skills, we have earned an outstanding nationwide reputation by representing thousands of individuals who have suffered serious and life-threatening injuries, or even death.
If you or a loved one has suffered serious injuries after using pharmaceutical medications or medical devices, please contact [http://www.druginjuryinformation.com/Home/Contact] the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.
The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.